logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2018 – PARP-inhibition in women with newly diagnosed advanced BRCA-mutated ovarian cancer increases PFS at three years to 60%

Maintenance therapy with olaparib decreased the risk of disease progression or death by 70% in the SOLO1 trial